The shares are listed on the HKEX

Davis Polk advised the underwriters in connection with Visen Pharmaceutical’s initial public offering and listing on the Hong Kong Stock Exchange and its international offering pursuant to Rule 144A / Regulation S. The gross proceeds from the offering were approximately HK$783.3 million prior to the exercise of the over-allotment option.

Visen Pharmaceutical is a late-stage, near-commercialization biopharmaceutical company focused on providing treatments in selected endocrinology diseases in China (including Hong Kong, Macau and Taiwan). Visen Pharmaceutical’s Core Product, lonapegsomatropin, is the only long-acting growth hormone that has demonstrated superior efficacy and comparable safety in active-controlled and parallel-group trial comparisons with daily human growth hormone, as validated in the completed Phase 3 pivotal trial in China.

The Davis Polk corporate team included partners Xuelin (Steve) Wang and Jason Xu, counsel Wendy Kan, registered foreign lawyer Pengyao (Raymond) Lai, associate Jamie Lai and legal managers Zhentao Hong and Qianwen Wang. Counsel Alon Gurfinkel and associates Kelli A. Rivers and Ya Sheng Lin provided tax advice. Members of the Davis Polk team are based in the Hong Kong, Beijing and London offices.

 

Copy link to share post